Carlo Rizzuto, Ph.D., is a Managing Director at Versant Ventures based in New York City. See sector focus and contact routes.
Carlo Rizzuto, Ph.D., is a Managing Director at Versant Ventures based in New York City, having joined the firm as a Principal in 2012 before advancing to his current role. He focuses on early-stage biotechnology and pharmaceutical investments, typically targeting Series A and Series B rounds with a published investment range of $100,000 to $5.0 million. Rizzuto specializes in biotech and medical devices, translating scientific innovation into therapeutic and diagnostic solutions while helping establish Versant’s presence in the Northeast. His notable portfolio includes Century Therapeutics (2021 IPO), Graphite Bio (2021 IPO), Repare (2020 IPO), and Pandion (sale). He serves as an independent director on Century Therapeutics’ board since March 2018, reflecting his deep operational involvement. Rizzuto brings prior experience from Novartis, where he led global product development, and from McKinsey & Company, where he advised pharmaceutical clients. While no distinctive public writing is cited in available sources, his background in virology (Ph.D. from Harvard) and biotech founding (engeneOS) shapes his scientific investment lens.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in New York.
Investors like Carlo Rizzuto · Full investor directory · Investor access · Company funding database